[1] 朱洁茹, 欧建平, 邢卫杰, 等. GnRH激动剂长方案与GnRH拮抗剂方案在不同年龄组、不同反应人群中的新鲜周期临床结局比较[J]. 中山大学学报, 2017, 38(5): 8.
[2] 靳镭, 徐蓓. 黄体生成素在卵泡发育中的作用及早卵泡期黄体生成素预处理[J]. 生殖医学杂志, 2014, 23(12): 4.
[3] MOKHTAR S, SADEGHI MR, AKHONDI MM, et al. ART outcomes in GnRH antagonist protocol (Flexible) and long GnRH agonist protocol during early follicular phase in patients with polycystic ovary syndrome: A randomized Clinical Trial[J]. J Reprod Infertil, 2015, 16(3): 148.
[4] TOFTAGER M, BOGSTAD J, BRYNDORF T, et al. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles[J]. Hum Reprod, 2016, 31(6): 1.
[5] SAHIN S, SELCUK S, DEVRANOGLU B, et al. Comparison of long GnRH agonist versus GnRH antagonist protocol in poor responders[J]. Turk J Obstet Gynecol, 2014, 11(4): 203. doi: 10.4274/tjod.80090
[6] HOWLES CM.The place of gonadotrophin-releasing hormone antagonists in reproductive medicine[J]. Reprod Biomed Online, 2002, 4(3): 64.
[7] REICHMAN DE, ZAKARIN L, CHAO K, et al. Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles[J]. Fertil Steril, 2014, 102(1): 99. doi: 10.1016/j.fertnstert.2014.04.010
[8] ZHANG D, XIA L, XU H, et al. Flexible low-dose gnrh antagonist protocol is effective in patients with sufficient ovarian reserve in IVF[J]. Front Endocrinol (Lausanne), 2018, 9: 767. doi: 10.3389/fendo.2018.00767
[9] BORM G, MANNAERTS B.Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group[J]. Hum Reprod, 2000, 15(7): 1490. doi: 10.1093/humrep/15.7.1490
[10] LAI Q, HU J, ZENG D, et al. Assessing the optimal dose for Cetrorelix in Chinese women undergoing ovarian stimulation during the course of IVF-ET treatment[J]. Am J Transl Res, 2014, 6(1): 78.
[11] 田阳, 谢铁男, 扈聪, 等. 不同卵巢储备功能病人血清GnSAF水平比较[J]. 山东医药, 2016, 56(35): 3.
[12] PECHSTEIN B, NAGARAJA VN, HERMANN R, et al. Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers[J]. J Clin Pharmacol, 2000, 40(3): 266. doi: 10.1177/00912700022008937
[13] OBERYE JJ, MANNAERTS BM, HUISMAN JA, et al. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part Ⅱ. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers[J]. Fertil Steril, 1999, 72(6): 1006. doi: 10.1016/S0015-0282(99)00414-8
[14] DUIJKERS IJ, KLIPPING C, WILLEMSEN WN, et al. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers[J]. Hum Reprod, 1998, 13(9): 2392. doi: 10.1093/humrep/13.9.2392